Advanced search
Publication Cover
Drug Metabolism Reviews Volume 54, 2022 - Issue 3
Submit an article Journal homepage
1,613
Views
1
CrossRef citations to date
0
Altmetric
Review Articles

Novel insights in drug transporter sciences: the year 2021 in review

Paresh P. Chothea Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5661-9011
ORCID Icon,
Pallabi Mitrab Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
,
Masanori Nakakariyac Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
,
Diane Ramsdend Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, MA, USA
,
Charles J. Rottere Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. (TDCA), 9625 Towne Centre Drive, San Diego, California, 92121, USA
,
Philip Sandovala Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA
&
Kimio Tohyamaa Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA
 show all
Pages 299-317 | Received 17 May 2022, Accepted 23 Jun 2022, Published online: 08 Jul 2022

References

  • Brunham LR, Baker S, Mammen A, Mancini GBJ, Rosenson RS. 2018. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.Cardiovasc Res. 114(8):1073–1081.
  • Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. 2005. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.Clin Pharmacol Ther. 78(4):330–341.
  • Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. 2007. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 82(6):726–733.
  • Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 16(12):873–879.
  • Safitri N, Alaina MF, Pitaloka DAE, Abdulah R. 2021. A narrative review of statin-induced rhabdomyolysis: molecular mechanism, risk factors, and management. Drug Healthc Patient Saf. 13:211–219.
  • Sibley RA, Katz A, Papadopoulos J. 2021. The interaction between rosuvastatin and ticagrelor leading to rhabdomyolysis: a case report and narrative review. Hosp Pharm. 56(5):537–542.
  • van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RPJ, Kenworthy KE, et al. 2012. Complete OATP1B1 and OATP1B3 deficiency causes human rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest. 122(2):519–528.
  • Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. 2009. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 54(17):1609–1616.
  • Yee SW, Giacomini MM, Shen H, Humphreys WG, Horng H, Brian W, Lai Y, Kroetz DL, Giacomini KM. 2019. Organic anion transporter polypeptide 1B1 polymorphism modulates the extent of drug-drug interaction and associated biomarker levels in healthy volunteers. Clin Transl Sci. 12(4):388–399.
  • Zhang L, Sarangi V, Ho MF, Moon I, Kalari KR, Wang L, Weinshilboum RM. 2021. SLCO1B1: application and limitations of deep mutational scanning for genomic missense variant function. Drug Metab Dispos. 49(5):395–404.

References

  • Bosgra S, van de Steeg E, Vlaming ML, Verhoeckx KC, Huisman MT, Verwei M, Wortelboer HM. 2014. Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling.Eur J Pharm Sci. 65:156–166.
  • Harwood MD, Achour B, Neuhoff S, Russell MR, Carlson G, Warhurst G, Rostami-Hodjegan A. 2016. In vitro-in vivo extrapolation scaling factors for intestinal P-glycoprotein and breast cancer resistance protein: part II. The impact of cross-laboratory variations of intestinal transporter relative expression factors on predicted drug disposition. Drug Metab Dispos. 44(3):476–480.
  • Kumar V, Yin J, Billington S, Prasad B, Brown CDA, Wang J, Unadkat JD. 2018. The importance of incorporating OCT2 plasma membrane expression and membrane potential in IVIVE of metformin renal secretory clearance. Drug Metab Dispos. 46(10):1441–1445.
  • Li CY, Hosey-Cojocari C, Basit A, Unadkat JD, Leeder JS, Prasad B. 2019. Optimized renal transporter quantification by using aquaporin 1 and aquaporin 2 as Anatomical markers: application in characterizing the ontogeny of renal transporters and its correlation with hepatic transporters in paired human samples. AAPS J. 21(5):88.
  • Sharma S, Suresh Ahire D, Prasad B. 2020. Utility of quantitative proteomics for enhancing the predictive ability of physiologically based pharmacokinetic models across disease states. J Clin Pharmacol. 60(Suppl 1):S17–S35.
  • Wegler C, Gaugaz FZ, Andersson TB, Wiśniewski JR, Busch D, Gröer C, Oswald S, Norén A, Weiss F, Hammer HS, et al. 2017. Variability in mass spectrometry-based quantification of clinically relevant drug transporters and drug metabolizing enzymes. Mol Pharm. 14(9):3142–3151.

References

  • Anoshchenko O, Storelli F, Unadkat JD. 2021. Successful prediction of human fetal exposure to P-glycoprotein substrate drugs using the proteomics-informed relative expression factor approach and PBPK modeling and simulation.Drug Metab Dispos. 49(10):919–928.
  • Costales C, Lin J, Kimoto E, Yamazaki S, Gosset JR, Rodrigues AD, Lazzaro S, West MA, West M, Varma MVS. 2021. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol. 10(9):1018–1031.
  • Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, et al. 2012. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos. 40(5):1007–1017.
  • Kim Y, Yoon S, Choi Y, Yoon SH, Cho JY, Jang IJ, Yu KS, Chung JY. 2019. Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. Sci Rep. 9(1):19410.
  • Kumar V, Yin M, Ishida K, Salphati L, Hop C, Rowbottom C, Xiao G, Lai Y, Mathias A, Chu X, et al. 2021. Prediction of transporter-mediated rosuvastatin hepatic uptake clearance and drug interaction in humans using proteomics-informed REF approach.Drug Metab Dispos. 49(2):159–168.
  • Storelli F, Anoshchenko O, Unadkat JD. 2021. Successful prediction of human steady-state unbound brain-to-plasma concentration ratio of P-gp substrates using the proteomics-informed relative expression factor approach. Clin Pharmacol Ther. 110(2):432–442.
  • Takahashi Y, Narumi K, Nadai T, Ueda H, Yamamura T, Furugen A, Kobayashi M. 2021. In vitro and in vivo evaluation of organic anion-transporting polypeptide 2B1-mediated pharmacokinetic interactions by apple polyphenols.Xenobiotica. 51(11):1318–1325.
  • Taskar KS, Pilla Reddy V, Burt H, Posada MM, Varma M, Zheng M, Ullah M, Emami Riedmaier A, Umehara KI, Snoeys J, et al. 2020. Physiologically-based pharmacokinetic models for evaluating membrane transporter mediated drug-drug interactions: current capabilities, case studies, future opportunities, and recommendations. Clin Pharmacol Ther. 107(5):1082–1115.

References

  • Lai Y, Mandlekar S, Shen H, Holenarsipur VK, Langish R, Rajanna P, Murugesan S, Gaud N, Selvam S, Date O, et al. 2016. Coproporphyrins in plasma and urine can be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition. J Pharmacol Exp Ther. 358(3):397–404.
  • Mori D, Kimoto E, Rago B, Kondo Y, King‐Ahmad A, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, et al. 2020. Dose‐dependent inhibition of OATP1B by rifampicin in healthy volunteers: comprehensive evaluation of candidate biomarkers and OATP1B probe drugs. Clin Pharmacol Ther. 107(4):1004–1013.
  • Neuvonen M, Hirvensalo P, Tornio A, Rago B, West M, Lazzaro S, Mathialagan S, Varma M, Cerny MA, Costales C, et al. 2021. Identification of glycochenodeoxycholate 3‐O‐glucuronide and glycodeoxycholate 3‐O‐glucuronide as highly sensitive and specific OATP1B1 biomarkers. Clin Pharmacol Ther. 109(3):646–657.

References

  • Chu X, Bleasby K, Chan GH, Nunes I, Evers R. 2016. The complexities of interpreting reversible elevated serum creatinine levels in drug development: does a correlation with inhibition of renal transporters exist? Drug Metab Dispos. 44(9):1498–1509.
  • Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, Sugiyama Y. 2011. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther. 89(6):837–844.
  • Miyake T, Mizuno T, Takehara I, Mochizuki T, Kimura M, Matsuki S, Irie S, Watanabe N, Kato Y, Ieiri I, et al. 2019. Elucidation of N1-methyladenosine as a potential surrogate biomarker for drug interaction studies involving renal organic cation transporters. Drug Metab Dispos. 47(11):1270–1280.
  • Müller F, Pontones CA, Renner B, Mieth M, Hoier E, Auge D, Maas R, Zolk O, Fromm MF. 2015. N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin–trimethoprim interaction. Eur J Clin Pharmacol. 71(1):85–94.
  • Stage TB, Brøsen K, Christensen MMH. 2015. A comprehensive review of drug–drug interactions with metformin. Clin Pharmacokinet. 54(8):811–824.

References

  • Mochizuki T, Mizuno T, Maeda K, Kusuhara H. 2021. Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development. Drug Metab Pharmacokinet. 37:100358.
  • Shen H, Holenarsipur VK, Mariappan TT, Drexler DM, Cantone JL, Rajanna P, Singh Gautam S, Zhang Y, Gan J, Shipkova PA, et al. 2019. Evidence for the validity of pyridoxic acid (PDA) as a plasma-based endogenous probe for OAT1 and OAT3 function in healthy subjects. J Pharmacol Exp Ther. 368(1):136–145.
  • Shen H, Nelson DM, Oliveira RV, Zhang Y, McNaney CA, Gu X, Chen W, Su C, Reily MD, Shipkova PA, et al. 2018. Discovery and validation of pyridoxic acid and homovanillic acid as novel endogenous plasma biomarkers of organic anion transporter (OAT) 1 and OAT3 in cynomolgus monkeys. Drug Metab Dispos. 46(2):178–188.

References

  • Barnett S, Ogungbenro K, Menochet K, Shen H, Humphreys WG, Galetin A. 2019. Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of oatp1b inhibition compared with rosuvastatin and coproporphyrin I. J Pharmacol Exp Ther. 368(1):125–135.
  • Rodrigues AD, Lai Y, Shen H, Varma MVS, Rowland A, Oswald S. 2020. Induction of human intestinal and hepatic organic anion transporting polypeptides: where is the evidence for its relevance in drug-drug interactions? Drug Metab Dispos. 48(3):205–216.

References

  • Rodrigues D, Rowland A. 2019. From endogenous compounds as biomarkers to plasma-derived nanovesicles as liquid biopsy; has the golden age of translational pharmacokinetics-absorption, distribution, metabolism, excretion-drug-drug interaction science finally arrived? Clin Pharmacol Ther. 105(6):1407–1420.
  • Zamek-Gliszczynski MJ, Patel M, Yang X, Lutz JD, Chu X, Brouwer KLR, Lai Y, Lee CA, Neuhoff S, Paine MF, et al. 2021. Intestinal P-gp and putative hepatic OATP1B induction: international transporter consortium perspective on drug development implications. Clin Pharmacol Ther. 109(1):55–64.

References

  • Elmeliegy M, Vourvahis M, Guo C, Wang DD. 2020. Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet. 59(6):699–714.
  • Guideline on the Investigation of Drug Interactions. European Medicines Agency, 21 June 2012. CPMP/EWP/560/95/Rev., Committee for Human Medicinal Products (CHMP) – finalized 2013.
  • Hariparsad N, Ramsden D, Taskar K, Badee J, Venkatakrishnan K, Reddy MB, Cabalu T, Mukherjee D, Rehmel J, Bolleddula J, et al. 2021. Current practices, gap analysis, and proposed workflows for pbpk modeling of cytochrome P450 induction: an industry perspective. Clin Pharmacol Ther. DOI:10.1002/cpt.2503.
  • Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, et al. 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 62(3):248–260.
  • Zhang Y, Guo X, Lin ET, Benet LZ. 1998. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.Drug Metab Dispos. 26(4):360–366.

References

  • Carney EF. 2020. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 16(5):251.
  • Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, et al. 2017. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 101(4):519–530.
  • Tatosian DA, Yee KL, Zhang Z, Mostoller K, Paul E, Sutradhar S, Larson P, Chhibber A, Wen J, Wang YJ, et al. 2021. A microdose cocktail to evaluate drug interactions in patients with renal impairment. Clin Pharmacol Ther. 109(2):403–415.

Reference

  • Saravanakumar A, Sadighi A, Ryu R, Akhlaghi F. 2019. Physicochemical properties, biotransformation, and transport pathways of established and newly approved medications: a systematic review of the top 200 most prescribed drugs vs. the FDA-approved drugs between 2005 and 2016.Clin Pharmacokinet. 58(10):1281–1294.

References

  • Lee W, Ha JM, Sugiyama Y. 2020. Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion-transporting polypeptides. J Biol Chem. 295(50):17349–17364.
  • Panfen E, Chen W, Zhang Y, Sinz M, Marathe P, Gan J, Shen H. 2019. Enhanced and persistent inhibition of organic cation transporter 1 activity by preincubation of cyclosporine A. Drug Metab Dispos. 47(11):1352–1360.
  • Tatrai P, Schweigler P, Poller B, Domange N, de Wilde R, Hanna I, Gaborik Z, Huth F. 2019. A Systematic in vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters. Drug Metab Dispos. 47(7):768–778.
  • Zhang J, Wang H, Fan Y, Yu Z, You G. 2021. Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination.Pharmacol Ther. 217:107647.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.